BioMarin Pharmaceutical/ US09061G1013 /
| 08/11/2024 21:59:56 | Chg. +0.18 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 67.08USD | +0.27% | 56,893 Turnover: 3.82 mill. |
-Bid Size: - | -Ask Size: - | 12.78 bill.USD | - | 75.36 |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 0.89 USD | 17.11% |
| EPS Diluted: | 0.87 USD | 16.00% |
| Revenues per Share: | 12.82 USD | 14.11% |
| Book Value per Share: | 26.24 USD | 6.34% |
| Cash Flow per Share: | 0.84 USD | -10.49% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 2,419.23 USD | 15.42% |
| Net Income: | 167.65 USD | 18.43% |
| Operating Cash Flow: | 159.26 USD | - |
| Cash and Cash Equivalents: | 755.13 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 75.36 | 108.34 |
| P/S Ratio: | 5.23 | 7.52 |
| P/BV ratio: | 2.56 | 3.67 |
| P/CF Ratio: | 79.46 | 114.23 |
| PEG: | 4.41 | 6.33 |
| Earnings Yield: | 1.33% | 0.92% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 12.78 bill. USD | 18.19 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 190.58 mill. | |
Profitability
| Gross Profit Margin: | 78.72% |
| EBIT Margin: | 6.54% |
| Net Profit Margin: | 6.93% |
| Return on Equity: | 3.39% |
| Return on Assets: | 2.45% |
Financial Strength
| Liquidity I / Cash Ratio: | 0.64% |
| Liquidity II / Quick Ratio: | 1.18% |
| Liquidity III / Current Ratio: | 2.51% |
| Debt / Equity Ratio: | 0.22% |
| Dynam. Debt / Equity Ratio: | 1,186.78% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 31/12/2023 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
